Phased Innovation Awards in AIDS Vaccine Research (R21/R33) | Apply Online

Opportunity Summary:

The Phased Innovation Awards in AIDS Vaccine Research (R21/R33) funding opportunity (PA-06-519) is an NIH grant program aimed at pushing forward the development of a preventive, or prophylactic, HIV/AIDS vaccine. The emphasis is on research ideas that are genuinely innovative and novel, including projects that may be considered high risk but could yield high impact if successful. NIH signals that it is interested in supporting work that can meaningfully improve how candidate AIDS vaccines are designed or evaluated, and it leaves the scientific scope intentionally broad: any line of investigation that contributes to an effective HIV vaccine is considered responsive.

A defining feature of this opportunity is what it does not fund. Clinical trials and first-in-human studies are explicitly out of scope, meaning applicants should not propose human efficacy or safety trials under this FOA. At the same time, NIH makes clear that certain kinds of clinical research can still fit, such as studies using clinical specimens. In other words, the program welcomes human-sourced materials and clinical data-driven research when it supports vaccine discovery or evaluation, but it draws the line at interventional clinical trials.

The program uses the NIH phased innovation mechanism that combines an R21 Phase I (exploratory) award with an R33 Phase II (developmental) award. This structure is designed to fund early proof-of-concept work first, then allow a faster transition into a larger, more developed project if the initial phase hits clearly defined milestones. The R21 phase supports milestone-driven feasibility or exploratory studies for up to two years. Investigators are expected to propose measurable milestones up front, and performance against those milestones is central to whether a project is eligible to transition. Projects that successfully complete the R21 phase milestones can be considered for the R33 phase, which supports expanded development for roughly an additional two to three years. Progression is not automatic: the R21 results are evaluated, and only projects that meet the expectations and remain programmatically aligned move forward.

Funding levels are also clearly defined and tied to each phase. For the R21 portion, direct costs are capped at $275,000 total across the two-year R21 period. For the R33 portion, direct costs are capped at $300,000 per year. NIH also indicates that advancement from R21 to R33 will be competitive and limited, anticipating that no more than about 50% of funded R21 awards will ultimately transition to the R33 phase. As with most NIH programs, final funding decisions depend on scientific and technical merit, program priorities, and the availability of funds.

In terms of who can apply, the eligibility pool is broad across U.S.-based organizations. Eligible applicants include public and private institutions of higher education, nonprofits (including both 501(c)(3) organizations and certain nonprofits without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, state governments, and certain other organizations as clarified in the full announcement. Faith-based and community-based organizations are eligible, and eligible federal agencies may apply. Foreign institutions are not eligible to apply under this FOA. Applicants may submit more than one application as long as each submission is scientifically distinct, which allows institutions or investigators with multiple vaccine concepts or platforms to pursue separate, non-overlapping ideas.

Administratively, the opportunity is categorized as discretionary grant funding in the health area, aligned with CFDA programs 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research). It does not require cost sharing or matching. The announcement listed multiple receipt dates (rather than a single deadline), with applicants directed to the full FOA text for the specific schedule and instructions. The complete announcement was posted by NIH and is accessible via the NIH Grants Guide page for PA-06-519.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Dissemination and Implementation Research in Health (R21)

Previous opportunity: Dissemination and Implementation Research in Health (R03)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 06 519

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 06 519) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 519", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.